Compare REGN & MSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | MSI |
|---|---|---|
| Founded | 1988 | 1928 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3B | 61.6B |
| IPO Year | 1991 | N/A |
| Metric | REGN | MSI |
|---|---|---|
| Price | $745.87 | $394.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 6 |
| Target Price | ★ $799.33 | $487.33 |
| AVG Volume (30 Days) | 858.3K | ★ 1.3M |
| Earning Date | 01-30-2026 | 02-12-2026 |
| Dividend Yield | 0.48% | ★ 1.24% |
| EPS Growth | 2.88 | ★ 36.31 |
| EPS | ★ 41.59 | 12.46 |
| Revenue | ★ $14,247,800,000.00 | $11,313,000,000.00 |
| Revenue This Year | $2.08 | $8.75 |
| Revenue Next Year | $6.82 | $8.24 |
| P/E Ratio | ★ $17.64 | $31.39 |
| Revenue Growth | 2.89 | ★ 6.18 |
| 52 Week Low | $476.49 | $359.36 |
| 52 Week High | $821.11 | $492.22 |
| Indicator | REGN | MSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 59.29 |
| Support Level | $718.38 | $390.65 |
| Resistance Level | $766.64 | $403.22 |
| Average True Range (ATR) | 21.57 | 7.29 |
| MACD | -7.93 | 1.81 |
| Stochastic Oscillator | 26.76 | 66.15 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Motorola Solutions is a leading provider of communications and analytics, primarily serving public safety departments as well as schools, hospitals, and businesses. The bulk of the firm's revenue comes from sales of land mobile radios and radio network infrastructure, but the firm also sells surveillance equipment, dispatch software, and other networking capabilities. Most of Motorola's revenue comes from government agencies, while roughly 25% comes from schools and private businesses. Motorola has customers in over 100 countries and in every state in the United States.